Drugs / BG-C137
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06625593 | Dec 2024 → Dec 2026 expected | neoplastic disease or syndrome | BeOne Medicines | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG-C137 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06625593 ↗ |
| Modality | Other / unclassified | “Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate” NCT06625593 ↗ |
| Route | Intravenous | “Administered intravenously” NCT06625593 ↗ |
| Target | FGFR2 | “Antibody-Drug Conjugate Targeting FGFR2b” NCT06625593 ↗ |